Back to news

IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2026: 83% Year-Over-Year Growth in U.S. Sales and Major Growth in U.S. Commercial Reach to 21 States

PR Newswire•18/11/2026•08:25 ET
0

Key Highlights

  • ➤U.S. sales increased 83% year over year through nine months 2026
  • ➤Revenue rose 26% to $2.6 million through nine months 2026
  • ➤Net loss widened to $12.995 million from $10.811 million
  • ➤U.S. commercial reach expanded to 21 states from 11
  • ➤China approved ProSense as Class III device; Netherlands distribution agreement signed

Expert Statements

Eyal Shamir, Chief Executive Officer of IceCure Medical

“We believe the first nine months of 2026 demonstrate the progress we made in translating our regulatory and clinical achievements into commercial growth, particularly in the United States. U.S. sales increased 83% year over year, while our commercial reach expanded from 11 to 21 states during the third quarter of 2026. At the same time, we are building the clinical foundation for broader adoption of ProSense® through the ChoICE Study. We believe these developments position us to continue driving physician adoption and expanding patient access to ProSense®”

IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2026: 83% Year-Over-Year Growth in U.S. Sales and Major Growth in U.S. Commercial Reach to 21 States PR Newswire

CAESAREA, Israel, Nov. 18, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today reported its financial and operating results as of and for the nine months ended September 30, 2026.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in